Comparing K2M Group (KTWO) and Invacare (IVC)

K2M Group (NASDAQ: KTWO) and Invacare (NYSE:IVC) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, risk, institutional ownership, earnings and analyst recommendations.


Invacare pays an annual dividend of $0.05 per share and has a dividend yield of 0.3%. K2M Group does not pay a dividend. Invacare pays out -2.1% of its earnings in the form of a dividend.

Institutional and Insider Ownership

99.2% of K2M Group shares are held by institutional investors. Comparatively, 94.7% of Invacare shares are held by institutional investors. 5.8% of K2M Group shares are held by company insiders. Comparatively, 2.6% of Invacare shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Risk and Volatility

K2M Group has a beta of 1.35, indicating that its stock price is 35% more volatile than the S&P 500. Comparatively, Invacare has a beta of 2.44, indicating that its stock price is 144% more volatile than the S&P 500.


This table compares K2M Group and Invacare’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
K2M Group -16.22% -16.02% -10.73%
Invacare -7.95% -13.33% -5.86%

Valuation & Earnings

This table compares K2M Group and Invacare’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
K2M Group $236.63 million 3.15 -$41.66 million ($0.97) -17.72
Invacare $1.05 billion 0.64 -$42.85 million ($2.35) -7.30

K2M Group has higher earnings, but lower revenue than Invacare. K2M Group is trading at a lower price-to-earnings ratio than Invacare, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings for K2M Group and Invacare, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
K2M Group 0 1 8 0 2.89
Invacare 0 1 2 0 2.67

K2M Group currently has a consensus target price of $24.38, indicating a potential upside of 41.80%. Invacare has a consensus target price of $15.00, indicating a potential downside of 12.54%. Given K2M Group’s stronger consensus rating and higher probable upside, equities analysts plainly believe K2M Group is more favorable than Invacare.


K2M Group beats Invacare on 8 of the 15 factors compared between the two stocks.

K2M Group Company Profile

K2M Group Holdings, Inc. is a medical device company focused on designing, developing and commercializing spine and minimally invasive technologies and techniques. The Company’s solutions are focused on achieving three-dimensional Total Body Balance. Its spine products are used by spine surgeons to treat spinal pathologies, such as deformity (primarily scoliosis), trauma and tumor. Its products consist of implants, disposables and instruments, which are marketed and sold primarily to hospitals for use by spine surgeons. As of December 31, 2016, its product portfolio consisted of 83 product lines that are used in complex spine, minimally invasive surgery (MIS) and degenerative surgeries. Its technologies include EVEREST, MESA, Rail 4D, Quicket Deformity, CASCADIA, CAPRI, SERENGETI, RAVINE and tifix. Its degenerative spine technologies are used to treat degenerative spine disorders and include products, such as cervical, thoracic and lumbar spinal fusion devices and interbody devices.

Invacare Company Profile

Invacare Corporation is a manufacturer and distributor for medical equipment used in non-acute care settings. The Company’s geographical segments are Europe; North America, which includes North America/Home Medical Equipment (North America/HME) and Institutional Products Group (IPG) segments, and Asia/Pacific. The Company manufactures and distributes three product categories: mobility and seating, lifestyle and respiratory therapy. It provides medical device solutions for congenital (cerebral palsy, muscular dystrophy and spina bifida), acquired (stroke, spinal cord injury, traumatic brain injury, post-acute recovery and pressure ulcers) and degenerative (amyotrophic lateral sclerosis, multiple sclerosis, chronic obstructive pulmonary disease (COPD), elderly and bariatric) ailments. The Company sells its products to home medical equipment providers with retail and e-commerce channels, residential living operators, distributors and government health services.

Receive News & Ratings for K2M Group Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for K2M Group Holdings Inc. and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply